Abstract:Objective eIF3a plays an essential role in the regulation of initiation of mRNA transcription and protein translation in mammalian cells.Recent studies showed that eIF3a protein is over-expressed in lung cancer tissues.The aims of this study were to explore whether eIF3a 2554G>A genetic polymorphism is associated with the susceptibility of lung cancer development and clinical responses to platinum-based chemotherapy in patients with lung cancer.Method Blood samples in all subjects were collected from the Xiangya hospital of Central South University,Changsha,Hunan Province,P.R.China. The genotyping analysis of eIF3a 2554G>A were determined by hemi-nested polymerase chain reaction restriction fragment length polymophism(PCR-RFLP).Results The allele frequencies of eIF3a 2554G>A in healthy control,lung cancer,small cell lung cancer,squamous cell carcinoma,and adenocarcinoma were 15.3%,10.9%,15.7%,13.4%,and 6.6%,respectively.The frequencies of eIF3a 2554 GG,GA and AA in patients with lung cancer were 78.8%,20.6%and 0.6%respectively.The frequencies of eIF3a 2554 GG,GA and AA in healthy control were 72.9%,23.5%and 3.5%respectively.There was no significant statistical difference in risk for lung cancer between the groups of GA,AA,GA+AA and the group of GG.After a balance in age,sex,and smoking status of all subjects,compared with group of GG genotype,the OR of the group of GA genotype,AA genotype and GA+AA genotype are 0.83(95% CI:0.49～1.41),0.18(95%CI:0.02～1.59) and 0.76(95%CI:0.45～1.27) respectively.In patients with small cell lung cancer,GA genotypic individuals had better platinum-based chemotherapy responsive tendency compared with GG genotype.The non-small cell lung cancer patients with GG genotype also had better chemotherapy responsive tendency compared with GA+AA genotype.Conclusion The data suggests that the genetic polymorphism of eIF3a 2554G>A may be associated with platinum-based chemotherapy sensitivity in Chinese patients with lung cancer.

Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

XBP1 Promoter Polymorphism Modulates Platinum-Based Chemotherapy Gastrointestinal Toxicity for Advanced Non-Small Cell Lung Cancer Patients

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Lack of Correlation Between ERCC1 (C8092A) Single Nucleotide Polymorphism and Efficacy/toxicity of Platinum Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Methylenetetrahydrofolate Reductase C677T Polymorphism Predicts Response and Time to Progression to Gemcitabine-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer in a Chinese Han Population

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Association of POLK Polymorphisms with Platinum-Based Chemotherapy Response and Severe Toxicity in Non-small Cell Lung Cancer Patients

Relationship between ERCC5-763A>G polymorphism and clinical outcome of patients with advanced colorectal cancer treated with piatinum-based chemotherapy

Rictor Polymorphisms Affect Efficiency Of Platinum-Based Chemotherapy In Chinese Non-Small-Cell Lung Cancer Patients

RAD18 Polymorphisms Are Associated with Platinum-Based Chemotherapy Toxicity in Chinese Patients with Non-Small Cell Lung Cancer

Relationship between ERCC5-763A>G polymorphism and clinical outcome of patients with advanced colorectal cancer treated with platinum-based chemotherapy

Association between well-characterized lung cancer lncRNA polymorphisms and platinum-based chemotherapy toxicity in Chinese patients with lung cancer

Relationship between ERCC5 promoter polymorphism and chemosensitivity of oxaliplatin-based chemotherapy in patients with advanced colorectal cancer

Genetic Polymorphism of SLC31A1 is Associated with Clinical Outcomes of Platinum-Based Chemotherapy in Non-Small-cell Lung Cancer Patients Through Modulating Microrna-Mediated Regulation.

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients.

Polymorphisms of ERCC1, XRCC1 and its association with survival to platin-based chemotherapy in advanced non-small cell lung cancer

Associations of genetic polymorphisms of the transporters organic cation transporter 2 ( OCT2 ), multidrug and toxin extrusion 1 ( MATE1 ), and ATP-binding cassette subfamily C member 2 ( ABCC2 ) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Impact of eIF3a 2554G>A genetic polymorphism on clinical sensitivity to platin-based chemotherapy in patients with lung cancer

Association Between Eif3α Polymorphism and Severe Toxicity Caused by Platinum‐based Chemotherapy in Non‐small Cell Lung Cancer Patients

An ERCC4 Regulatory Variant Predicts Grade-3 Or-4 Toxicities in Patients with Advanced Non-Small Cell Lung Cancer Treated by Platinum-Based Therapy